Abstract
The role of cannabinoid receptors in inflammation has been the topic of many research endeavors. Despite this effort, to date the involvement of the endocannabinoid system (ECS) in inflammation remains obscure. The ambiguity of cannabinoid involvement may be explained by the existence of cannabinoid receptors, other than CB1 and CB2, or a consequence of interaction of endocannabinoids with other signaling systems. GPR55 has been proposed to be a cannabinoid receptor; however the interaction of the endocannabinoid system with GPR55 remains elusive. Consequently this study set about to examine the effects of the endocannabinoids, anandamide (AEA) and virodhamine, on GPR55 mediated signaling. Specifically, we assessed changes in β-arrestin2 (βarr2) distribution and GPR55 receptor internalization following activation by lysophosphatidylinositol (LPI), the synthetic cannabinoid ligand SR141716A, and new selective synthetic GPR55 agonists. Data obtained from the experiments presented herein demonstrate that AEA and virodhamine modulate agonist-mediated recruitment of βarr2. AEA and virodhamine act as partial agonists; enhancing the agonist effect at low concentrations and inhibiting it at high concentrations. Furthermore, both virodhamine and AEA significantly attenuated agonist-induced internalization of GPR55. These effects are attributed to the expression of GPR55, and not CB1 and CB2 receptors, as we have established negligible expression of CB1 and CB2 in these GPR55-transfected U2OS cells. The identification of select endocannabinoids as GPR55 modulators will aide in elucidating the function of GPR55 in the ECS.
Similar content being viewed by others
Abbreviations
- AEA:
-
Anandamide; N-arachidonyl ethanolamine
- 2-AG:
-
2-arachidonyl glycerol
- βarr2:
-
β-arrestin2
- BV2:
-
murine microglial cell line
- BSA:
-
bovine serum albumin
- CB1 :
-
cannabinoid receptor type 1
- CB2 :
-
cannabinoid receptor type 2
- CHO:
-
Chinese hamster ovary cell line
- DMEM:
-
Dulbecco’s modified Eagle’s medium
- ECS:
-
endocannabinoid system
- FBS:
-
fetal bovine serum
- FCA:
-
Freund’s complete adjuvant
- GFP:
-
Green Fluorescent Protein
- GPCR:
-
G-protein coupled receptor
- HBSS:
-
Hanks’ balanced salt solution
- HA:
-
hemagglutinin
- HEK293:
-
human embryonic kidney cell line
- IFN-γ:
-
interferon gamma
- LDH:
-
lactate dehydrogenase
- LPI:
-
lysophosphatidylinositol
- LPS:
-
lipopolysaccharide
- ML184 (CID2440433):
-
3-[4-(2,3-dimethylphenyl)piperazine-1-carbonyl]-N,N-dimethyl-4-pyrrolidin-1-ylbenzenesulfonamide
- ML185 (CID1374043):
-
N-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-2-[(4-methyl-[1,2,4]triazolo[4,3-a]quinolin-1-yl)sulfanyl]acetamide
- ML186 (CID15945391):
-
N-(2-methoxy-5-morpholin-4-ylsulfonylphenyl)-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxamide
- PBS:
-
phosphate-buffered saline
- qRT-PCR:
-
quantitative real time PCR
- RT-PCR:
-
reverse transcriptase-polymerase chain reaction
- SR141716A:
-
N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide
- U2OS:
-
osteosarcoma cell line
- Virodhamine:
-
O-arachidonoyl ethanolamine
References
Abood ME, Rizvi G, Sallapudi N, McAllister SD (2001) Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci Lett 309(3):197–201
Anavi-Goffer S, Baillie G, Irving AJ, Gertsch J, Greig IR, Pertwee RG, Ross RA (2012) Modulation of L-alpha-Lysophosphatidylinositol/GPR55 Mitogen-activated Protein Kinase (MAPK) Signaling by Cannabinoids. J Biol Chem 287(1):91–104. doi:10.1074/jbc.M111.296020
Andradas C, Caffarel MM, Perez-Gomez E, Salazar M, Lorente M, Velasco G, Guzman M, Sanchez C (2011) The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 30(2):245–252. doi:10.1038/onc.2010.402
Balenga NA, Aflaki E, Kargl J, Platzer W, Schroder R, Blattermann S, Kostenis E, Brown AJ, Heinemann A, Waldhoer M (2011) GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res. doi:10.1038/cr.2011.60
Bondarenko AI, Malli R, Graier WF (2011) The GPR55 agonist lysophosphatidylinositol acts as an intracellular messenger and bidirectionally modulates Ca2+ -activated large-conductance K + channels in endothelial cells. Pflugers Arch 461(1):177–189. doi:10.1007/s00424-010-0898-x
Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton SA (1995) Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci U S A 92(16):7162–7166
Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (New York, NY) 258:1946–1949
Di Marzo V, Melck D, Bisogno T, De Petrocellis L (1998) Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 21(12):521–528
Ford LA, Roelofs AJ, Anavi-Goffer S, Mowat L, Simpson DG, Irving AJ, Rogers MJ, Rajnicek AM, Ross RA (2010) A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol 160(3):762–771. doi:10.1111/j.1476-5381.2010.00743.x
Grimsey NL, Goodfellow CE, Dragunow M, Glass M (2011) Cannabinoid receptor 2 undergoes Rab5-mediated internalization and recycles via a Rab11-dependent pathway. Biochim Biophys Acta 1813(8):1554–1560. doi:10.1016/j.bbamcr.2011.05.010
Henstridge CM, Balenga NA, Ford LA, Ross RA, Waldhoer M, Irving AJ (2009) The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J 23(1):183–193. doi:10.1096/fj.08-108670
Henstridge CM, Balenga NA, Schroder R, Kargl JK, Platzer W, Martini L, Arthur S, Penman J, Whistler JL, Kostenis E, Waldhoer M, Irving AJ (2010) GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol 160(3):604–614. doi:10.1111/j.1476-5381.2009.00625.x
Heynen-Genel S, Dahl R, Shi S, Milan L, Hariharan S, Bravo Y, Sergienko E, Hedrick M, Dad S, Stonich D, Su Y, Vicchiarelli M, Mangravita-Novo A, Smith LH, Chung TDY, Sharir H, Barak LS, Abood ME (2010) Screening for Selective Ligands for GPR55 - Agonists. Probe Reports from the Molecular Libraries Program, 2011/11/18 edn., Bethesda, MD. doi:NBK66152 [bookaccession]
Huang L, Ramirez JC, Frampton GA, Golden LE, Quinn MA, Pae HY, Horvat D, Liang LJ, DeMorrow S (2011) Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor. Lab Invest 91(7):1007–1017. doi:10.1038/labinvest.2011.62
Irving A (2011) New blood brothers: the GPR55 and CB(2) partnership. Cell Res. doi:10.1038/cr.2011.77
Joseph J, Niggemann B, Zaenker KS, Entschladen F (2004) Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol Immunother 53(8):723–728. doi:10.1007/s00262-004-0509-9 [doi]
Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS, Abood ME (2009) Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem 284(43):29817–29827. doi:10.1074/jbc.M109.050187
Kotsikorou E, Madrigal KE, Hurst DP, Sharir H, Lynch DL, Heynen-Genel S, Milan LB, Chung TD, Seltzman HH, Bai Y, Caron MG, Barak L, Abood ME, Reggio PH (2011) Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry 50(25):5633–5647. doi:10.1021/bi200010k
Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K (2008) GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 105(7):2699–2704. doi:10.1073/pnas.0711278105
Mitrirattanakul S, Ramakul N, Guerrero AV, Matsuka Y, Ono T, Iwase H, Mackie K, Faull KF, Spigelman I (2006) Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain 126:102–114
Oka S, Nakajima K, Yamashita A, Kishimoto S, Sugiura T (2007) Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 362(4):928–934. doi:10.1016/j.bbrc.2007.08.078
Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB. Pharmacol Rev 62(4):588–631. doi:10.1124/pr.110.003004
Petrosino S, Palazzo E, de Novellis V, Bisogno T, Rossi F, Maione S, Di Marzo V (2007) Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 52:415–422
Pietr M, Kozela E, Levy R, Rimmerman N, Lin YH, Stella N, Vogel Z, Juknat A (2009) Differential changes in GPR55 during microglial cell activation. FEBS Lett 583(12):2071–2076. doi:10.1016/j.febslet.2009.05.028
Pineiro R, Maffucci T, Falasca M (2011) The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 30(2):142–152. doi:10.1038/onc.2010.417
Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301(3):1020–1024
Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152(7):1092–1101. doi:10.1038/sj.bjp.0707460
Scotter EL, Abood ME, Glass M (2010) The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol 160:480–498
Showalter VM, Compton DR, Martin BR, Abood ME (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278(3):989–999
Staton PC, Hatcher JP, Walker DJ, Morrison AD, Shapland EM, Hughes JP, Chong E, Mander PK, Green PJ, Billinton A, Fulleylove M, Lancaster HC, Smith JC, Bailey LT, Wise A, Brown AJ, Richardson JC, Chessell IP (2008) The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 139(1):225–236. doi:10.1016/j.pain.2008.04.006
Sugiura T, Waku K (2000) 2-Arachidonoylglycerol and the cannabinoid receptors. Chem Phys Lipids 108:89–106
Tao Q, Abood ME (1998) Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling. J Pharmacol Exp Ther 285(2):651–658
Vrecl M, Norregaard PK, Almholt DL, Elster L, Pogacnik A, Heding A (2009) Beta-arrestin-based Bret2 screening assay for the “non”-beta-arrestin binding CB1 receptor. J Biomol Screen 14(4):371–380. doi:10.1177/1087057109333101
Walter L, Stella N (2004) Cannabinoids and neuroinflammation. Br J Pharmacol 141(5):775–785. doi:10.1038/sj.bjp.0705667
Whyte LS, Ryberg E, Sims NA, Ridge SA, Mackie K, Greasley PJ, Ross RA, Rogers MJ (2009) The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A 106(38):16511–16516. doi:10.1073/pnas.0902743106
Yin H, Chu A, Li W, Wang B, Shelton F, Otero F, Nguyen DG, Caldwell JS, Chen YA (2009) Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem 284(18):12328–12338. doi:10.1074/jbc.M806516200
Acknowledgments
This research was supported by the National Institutes of Health National Institute on Drug Abuse [Grants DA023204, DA005274, T32DA07237, DA13429]. We would like to thank Dr. Pingwei Zhao for providing the plug-in for data quantification, Drs. Lawrence Barak and Marc Caron for providing the GPR55/βarr2-GFP U2OS cells and express gratitude to Mrs. Genevieve V. Regan for her valuable assistance with the confocal imaging.
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sharir, H., Console-Bram, L., Mundy, C. et al. The Endocannabinoids Anandamide and Virodhamine Modulate the Activity of the Candidate Cannabinoid Receptor GPR55. J Neuroimmune Pharmacol 7, 856–865 (2012). https://doi.org/10.1007/s11481-012-9351-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11481-012-9351-6